iBB

Candida auris is an emerging human pathogen, considered a serious health threat by the CDC, being associated with antifungal drug resistance and hospital candidiasis outbreaks. Aiming an increased understanding of the unique features of this new fungal pathogen, both in terms of drug resistance and metabolic potential, the construction and validation of a global stoichiometric model describing the whole metabolic network in this human pathogen, as well as its exploitation in drug target discovery, stemming from a collaboration between researchers from iBB (Romeu Viana, Tiago Carreiro, Diogo Couceiro, Miguel Cacho Teixeira), ITQB-NOVA (Isabel Rocha) and CEB-UMinho (Óscar Dias), was just published in FEMS Yeast Research.